Frontotemporal Dementia Trial of Intranasal Oxytocin

  • Study Director: Adam Boxer, MD, PhD
  • Sponsor: Lawson Health Research Institute
  • Status: Active trial, closed to new enrollment
  • Official Study Title: Intranasal Oxytocin for Frontotemporal Dementia (FOXY)
  • ClinicalTrials.gov Identifier: NCT03260920
  • Conditions Studied: Frontotemporal dementia (FTD)
  • Intervention: Syntocinon
  • Phase: Phase 2
  • Duration of Participation:

Purpose of the Study

The purpose of this study is to evaluate the safety and tolerability of Syntocinon given intranasally compared to placebo in patients with frontotemporal dementia/Pick’s disease (FTD).

Eligibility

What to Expect

Testing: Neurological and physical examinations, MRIs, one PET scan, at least two lumbar punctures, cognitive testing and neuropsychiatric assessments, EKGs, telephone calls, blood and urine specimen collection, and vital signs

The Frequency of Visits: Every 6 weeks

Materials Needed Before Evaluation: Prior to participating in the trial, the patient will need a diagnosis of probable frontotemporal dementia/Pick’s disease.

Costs: No costs will be charged for any of the study procedures. Parking will be validated at UCSF public garages for all study visits.

Contact Information

Coordinator: [email protected]
Clinical Trials Nurse: Whitney Walker, MS, CNS, RN – [email protected], 415.353.7532